Peptech is developing PMX-53, a complement C5a inhibitor for the potential treatment of inflammatory disorders, including rheumatoid arthritis and psoriasis. Phase Ib/IIa clinical trials have been completed for both indications.
|Journal||Current Opinion in Molecular Therapeutics|
|Number of pages||10|
|Publication status||Published - 01.12.2006|